Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients

This study has been completed.
Information provided by (Responsible Party):
Desitin Arzneimittel GmbH Identifier:
First received: March 12, 2010
Last updated: February 28, 2013
Last verified: March 2010
The aim of the observational study is to investigate the safety of oxcarbazepine extended release (ER) during long-term therapy in epileptic patients. In addition, quality of life parameters should be documented if assessed.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Efficacy and Safety of an ER-formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients Under Consideration of Quality of Life Parameters

Resource links provided by NLM:

Further study details as provided by Desitin Arzneimittel GmbH:

Primary Outcome Measures:
  • tolerability and safety [ Time Frame: 12 months per patient ] [ Designated as safety issue: Yes ]

Enrollment: 225
Study Start Date: February 2010
Study Completion Date: October 2012
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
newly diagnosed epileptic patients or patients who will be switched from other antiepileptic drugs to oxcarbazepine ER

Inclusion Criteria:

  • patients with focal epileptic seizures with or without secondary generalised tonic-clonic seizures
  • mono- or combination therapy
  • male and female from the age of 6

Exclusion Criteria:

  • hypersensitivity to oxcarbazepine MR or one of its excipients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01086501

Dr. Stephan Arnold
Munich, Bavaria, Germany, 80333
Sponsors and Collaborators
Desitin Arzneimittel GmbH
Principal Investigator: Stephan Arnold, MD Private Practice
  More Information

Responsible Party: Desitin Arzneimittel GmbH Identifier: NCT01086501     History of Changes
Other Study ID Numbers: OXC-044/K 
Study First Received: March 12, 2010
Last Updated: February 28, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Desitin Arzneimittel GmbH:
open, non-interventional

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers processed this record on October 25, 2016